Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 7/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5247186 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL848884 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL850125 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL865736 | 0.91 | LMNA (0.48) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL5679801 | 0.85 | TSHR (0.48) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL5251554 | 0.85 | ALDH1A1 (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL8817964 | 0.84 | LMNA (0.48) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL26697618 | 0.84 | MEN1 (0.49) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL26665132 | 0.84 | MEN1 (0.49) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL26697569 | 0.84 | MEN1 (0.49) | TSHRLMNANFKB1PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411896-B1 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LTD (GB) | 2006-03-22 | — | — | EP | claimed |
| US-20040234556-A1 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | claimed |
| EP-1411896-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-04-28 | — | — | EP | claimed |
| WO-2003013610-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2003-02-20 | — | — | WO | claimed |
| EP-1486203-B1 | Surfactant compounds and uses thereof | GLAXO GROUP LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-7195752-B2 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1411896-B1 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LTD (GB) | 2006-03-22 | — | — | EP | disclosed |
| EP-1486203-A2 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-20040234556-A1 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1411896-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003013610-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
| US-4318914-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| US-4310545-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4305959-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
| US-4205085-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234556-A1 | Surfactant compounds and uses thereof | PFN1, SGMS1, SPTLC1 | TSHR 3083/4885LMNA 836/4885NFKB1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.